Biodexa Pharmaceuticals

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company headquartered in Cardiff, United Kingdom, with a strategic focus on developing treatments for significant unmet medical needs. Originally founded as Midatech Pharma in 2010, the company rebranded to Biodexa Pharmaceuticals on January 23, 2023, to reflect its evolution from a drug delivery-focused entity to a multi-asset therapeutics company. The firm went public via an IPO in 2015 and has since executed strategic acquisitions, including DARA BioSciences in 2015 and Q Chip Ltd in 2016, to expand its capabilities and commercial footprint.

The company's business model is centered on the clinical development of its pipeline assets, with a revenue strategy that anticipates future product sales, licensing agreements for its technologies, and strategic partnerships that may generate milestone payments and royalties. The leadership team, helmed by CEO and CFO Stephen Stamp, possesses extensive experience in public healthcare companies, guiding Biodexa through its clinical and corporate milestones. The company has undergone financial restructuring, including reverse ADR splits, to maintain compliance with Nasdaq's listing requirements.

Biodexa's development pipeline features several candidates. The lead program, MTX110, is a solubilized formulation of panobinostat, a histone deacetylase (HDAC) inhibitor. This formulation is engineered for direct delivery to brain tumors via Convection-Enhanced Delivery (CED), a technique designed to bypass the blood-brain barrier. This method allows for the administration of high-potency doses directly at the tumor site, aiming to reduce systemic toxicity. MTX110 is under clinical investigation for aggressive and rare brain cancers such as recurrent glioblastoma and diffuse midline glioma (DMG), with ongoing Phase I and II trials. Other programs in the pipeline include Tolimidone, a Phase 2a candidate for Type 1 diabetes, and eRapa, a proprietary oral formulation of rapamycin being prepared for a Phase 3 study in Familial Adenomatous Polyposis (FAP).